MCID: INT002
MIFTS: 56

Intermittent Claudication malady

Categories: Cardiovascular diseases

Aliases & Classifications for Intermittent Claudication

Aliases & Descriptions for Intermittent Claudication:

Name: Intermittent Claudication 38 12 52 42 14 69
Intermittent Claudication Nos 12
Charcot's Syndrome 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3669
ICD10 33 I73.9
MeSH 42 D007383
UMLS 69 C0021775

Summaries for Intermittent Claudication

MalaCards based summary : Intermittent Claudication, also known as intermittent claudication nos, is related to aortic aneurysm and limb ischemia, and has symptoms including asthenia, body temperature changes and cyanosis. An important gene associated with Intermittent Claudication is HTR2A (5-Hydroxytryptamine Receptor 2A), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Formation of Fibrin Clot (Clotting Cascade). The drugs Cilostazol and Menthol have been mentioned in the context of this disorder. Affiliated tissues include Placenta, endothelial and smooth muscle, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 71 Intermittent claudication (Latin: claudicatio intermittens) is a symptom that describes muscle pain on... more...

Related Diseases for Intermittent Claudication

Diseases related to Intermittent Claudication via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 244)
id Related Disease Score Top Affiliating Genes
1 aortic aneurysm 30.2 VEGFA VWF
2 limb ischemia 30.0 ACE CRP HTR2A IL6 SELP
3 atherosclerosis 29.9 APOH IL6
4 myocardial infarction 28.1 ACE ALB CRP F2 IL6 SELP
5 peripheral artery disease 11.4
6 critical limb ischemia 11.3
7 artery disease 10.5
8 vcl-related dilated cardiomyopathy 10.3 SELP VWF
9 iron metabolism disease 10.3 ACE CRP
10 listeriosis 10.3 ACE VWF
11 stt3a-cdg and stt3b-cdg 10.2 SERPINC1 SERPINE1
12 endotheliitis 10.2
13 hereditary endotheliopathy, retinopathy, nephropathy, and stroke 10.2 SELP SERPINC1
14 acute infection of pinna 10.2 CRP F2
15 ischemia 10.2
16 carbohydrate metabolic disorder 10.2 ACE SERPINC1
17 cetp-related hyperalphalipoproteinemia 10.2 ACE SERPINE1 VWF
18 brazilian hemorrhagic fever 10.2 SERPINC1 SERPINE1
19 alpha-2-macroglobulin deficiency 10.2 F2 VWF
20 septic myocarditis 10.2 SELP SERPINC1 VWF
21 submucous uterine fibroid 10.2 ALB VEGFA
22 deafness, autosomal recessive 79 10.2 ACE CRP VWF
23 monocular exotropia 10.2 SERPINC1 SERPINE1 VWF
24 intra-abdominal lymph node mast cell malignancy 10.2 ACE CRP SELP
25 spinal stenosis 10.2
26 ceroid lipofuscinosis, neuronal, kufs type, adult onset 10.2 ACE CRP VWF
27 familial progressive hyperpigmentation 10.2 ACE F2
28 citrulline transport defect 10.2 CRP F2
29 nondystrophic myotonia 10.2 ALB F2
30 hypersensitivity syndrome, carbamazepine-induced 10.2 ALB VEGFA
31 prostatic hypertrophy 10.2 F2 SELP VWF
32 testicular lymphoma 10.2 ACE CRP SELP
33 lipomatosis 10.2 ACE CRP SERPINE1
34 zellweger syndrome 10.2 ALB VEGFA VWF
35 mental retardation, autosomal recessive 27 10.2 SERPINC1 SERPINE1 VEGFA
36 bile duct mucoepidermoid carcinoma 10.2 ALB CRP VWF
37 miller-dieker lissencephaly syndrome 10.2 F2 SERPINC1
38 atrophic nonflaccid tympanic membrane 10.2 F2 SELP VWF
39 influenza 10.1 F2 SERPINC1
40 pyridoxamine 5'-phosphate oxidase deficiency 10.1 F2 SELP VWF
41 pancreatic ductal carcinoma 10.1 F2 SERPINC1
42 schizotypal personality disorder 10.1 ACE ALB CRP
43 cataract 10.1 ALB CRP SERPINC1
44 spondyloarthropathy 2 10.1 ACE ALB VEGFA
45 synostosis 10.1 CRP F2
46 multinodular goiter 10.1 APOH CRP VEGFA
47 chromosomal disease 10.1 F2 SERPINE1 VEGFA
48 mixed epithelial tumor of ovary 10.1 F2 SERPINC1
49 hypertrichosis 10.1 APOH SERPINC1 VWF
50 essential thrombocythemia 10.1 F2 SERPINC1 VWF

Graphical network of the top 20 diseases related to Intermittent Claudication:



Diseases related to Intermittent Claudication

Symptoms & Phenotypes for Intermittent Claudication

UMLS symptoms related to Intermittent Claudication:


asthenia, body temperature changes, cyanosis, edema, eye manifestations, fatigue, flushing, oral manifestations, signs and symptoms, signs and symptoms, digestive, signs and symptoms, respiratory, skin manifestations, chills, polydipsia, renal colic, hot flushes, urological manifestations, mobility limitation, prodromal symptoms, hypertriglyceridemic waist, medically unexplained symptoms

MGI Mouse Phenotypes related to Intermittent Claudication:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.13 SERPINE1 TNNT2 VEGFA VWF ACE CRP
2 homeostasis/metabolism MP:0005376 10.1 ACE ALB APOH CRP F2 IL6
3 hematopoietic system MP:0005397 9.97 ACE F2 IL6 SELP SERPINC1 SERPINE1
4 immune system MP:0005387 9.91 ACE CRP F2 IL6 SELP SERPINC1
5 digestive/alimentary MP:0005381 9.88 ALB F2 HTR2A IL6 VEGFA VWF
6 liver/biliary system MP:0005370 9.7 ACE ALB IL6 SELP SERPINC1 SERPINE1
7 mortality/aging MP:0010768 9.7 ACE ALB APOH F2 IL6 SELP
8 renal/urinary system MP:0005367 9.17 ACE ALB IL6 SELP SERPINC1 SERPINE1

Drugs & Therapeutics for Intermittent Claudication

Drugs for Intermittent Claudication (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 160)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cilostazol Approved Phase 4,Phase 2,Phase 1 73963-72-1 2754
2
Menthol Approved Phase 4,Phase 3 2216-51-5 16666
3
Aspirin Approved, Vet_approved Phase 4,Phase 2 50-78-2 2244
4
Heparin Approved, Investigational Phase 4,Phase 3 9005-49-6 772 46507594
5
Ramipril Approved Phase 4 87333-19-5 5362129
6
Allopurinol Approved Phase 4 315-30-0 2094
7
Alprostadil Approved, Investigational Phase 4,Phase 3,Phase 2 745-65-3 149351
8
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
9
Pentoxifylline Approved, Investigational Phase 4,Phase 3 6493-05-6 4740
10
Pioglitazone Approved, Investigational Phase 4,Phase 2,Phase 3 111025-46-8 4829
11
Ticagrelor Approved Phase 4 274693-27-5 9871419
12
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
13
Vorapaxar Approved Phase 4 618385-01-6
14
Paclitaxel Approved, Vet_approved Phase 4,Phase 3 33069-62-4 36314
15
Benzocaine Approved Phase 4 1994-09-7, 94-09-7 2337
16
Metformin Approved Phase 4 657-24-9 14219 4091
17
Candesartan Approved Phase 4 139481-59-7 2541
18
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
19
Losartan Approved Phase 4 114798-26-4 3961
20
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
21
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
22
Gliclazide Approved Phase 4 21187-98-4 3475
23
Glimepiride Approved Phase 4 93479-97-1 3476
24
Glyburide Approved Phase 4 10238-21-8 3488
25
Clopidogrel Approved, Nutraceutical Phase 4,Phase 2 120202-66-6, 113665-84-2 60606
26 tannic acid Approved, Nutraceutical Phase 4
27 Anti-Asthmatic Agents Phase 4,Phase 2,Phase 1
28 Autonomic Agents Phase 4,Phase 2,Phase 1
29 Bronchodilator Agents Phase 4,Phase 2,Phase 1
30 Fibrinolytic Agents Phase 4,Phase 3,Phase 2,Phase 1
31 Neuroprotective Agents Phase 4,Phase 2,Phase 1
32 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 1
33 Phosphodiesterase 3 Inhibitors Phase 4,Phase 2,Phase 1
34 Phosphodiesterase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
35 Platelet Aggregation Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
36 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
37 Respiratory System Agents Phase 4,Phase 2,Phase 1
38 Vasodilator Agents Phase 4,Phase 3,Phase 2,Phase 1
39 Analgesics Phase 4,Phase 2
40 Antimetabolites Phase 4,Phase 3,Phase 2
41 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4,Phase 3,Phase 2
42 Analgesics, Non-Narcotic Phase 4,Phase 2
43 Anti-Inflammatory Agents Phase 4,Phase 2
44 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2
45 Antipyretics Phase 4,Phase 2
46 Antirheumatic Agents Phase 4,Phase 2
47 Cyclooxygenase Inhibitors Phase 4,Phase 2
48 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
49 Purinergic P2 Receptor Antagonists Phase 4,Phase 2
50 Purinergic P2Y Receptor Antagonists Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 174)
id Name Status NCT ID Phase
1 ATHERO: Advanced Technology Halting Early Re-Stenosis and Occlusion Unknown status NCT00407940 Phase 4
2 Effects of Cilostazol on Plasma Adipocytokine and Arterial Stiffness Unknown status NCT00573950 Phase 4
3 Multifactorial Intervention on Cardiovascular Risk Factors in Subjects With Peripheral Arterial Disease Unknown status NCT00144937 Phase 4
4 Self Expanding Nitinol Stent Versus Percutaneous Transluminal Arterial Angioplasty (PTA) With Optional Bailout Stenting in Case of PTA Failure in Patients With Symptomatic Critical Limb Ischemia or Severe Intermittent Claudication (EXPAND) Completed NCT00906022 Phase 4
5 Evaluation of Cilostazol in Combination With L-Carnitine Completed NCT00822172 Phase 4
6 Neurogenic Intermittent Claudication Evaluation Study Completed NCT00905359 Phase 4
7 Resistance to Aspirin and/or Clopidogrel Among Patients With PAD. Completed NCT00262561 Phase 4
8 Intermittent Neurogenic Claudication Treatment With APERIUS® Completed NCT00887744 Phase 4
9 Angioplasty in Peripheral Arterial Disease and Endothelial Function Completed NCT00660634 Phase 4
10 PTA vs. Primary Stenting of SFA Using Self-Expandable Nitinol Stents Completed NCT00715416 Phase 4
11 Choice of Material for Above-Knee Femoro-Popliteal Bypass Prosthetic Graft (PopUp) Completed NCT00300690 Phase 4
12 Clinical and Cost Effectiveness of ACE Inhibitor, Ramipril, in Intermittent Claudicants Completed NCT01037530 Phase 4
13 DURABILITY-200: EverFlex 200mm Long Nitinol Stents in TASC C&D Femoropopliteal Lesions Completed NCT00637741 Phase 4
14 Efficacy Study of Iliac Stents to Treat TASC A-B-C-D Iliac Artery Lesions Completed NCT00764777 Phase 4
15 Allopurinol as a Possible Oxygen Sparing Agent During Exercise in Peripheral Arterial Disease Completed NCT01147705 Phase 4
16 The Effects of Ramipril on Clinical Symptoms in Patients With Peripheral Arterial Disease Completed NCT00168467 Phase 4
17 A Study to Evaluate Efficacy of 『Opast Tablet』for Neurologic Claudication in Patients With Lumbar Spinal Stenosis Completed NCT01888536 Phase 4
18 GORE VIABAHN ENDOPROSTHESIS Peripheral Vascular Disease Study Completed NCT00228384 Phase 4
19 Intermittent Mechanical Compression For Peripheral Arterial Disease Completed NCT00855673 Phase 4
20 Effect of olmesaRtan on Walking distancE and quaLIty of lifE in Peripheral Artery Disease Patients With Hypertension Treated For Intermittent Claudication (RELIEF) Recruiting NCT02373462 Phase 4
21 Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial) Recruiting NCT02660866 Phase 4
22 Paclitaxel Eluting Stent or Exercise for Thigh Atherosclerosis Recruiting NCT02033135 Phase 4
23 Metformin, Muscle Energetics, and Vascular Function in Older Adults With Peripheral Artery Disease Recruiting NCT01901224 Phase 4
24 Renoprotection by Pentoxifylline and Angiotensin Receptor Blocker in Chronic Kidney Disease (CKD) Recruiting NCT01377285 Phase 4
25 Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents.Intervention Trial Active, not recruiting NCT00700856 Phase 4
26 The Effects of Metformin on Functional Capacity in Individuals With Peripheral Artery Disease-Related Intermittent Claudication Terminated NCT01799057 Phase 4
27 Study on the Treatment of Degenerative Lumbar Spine Stenosis With a Percutaneous Interspinous Implant Terminated NCT01057641 Phase 4
28 Balloon Angioplasty vs. Cutting Balloon Angioplasty of Femoropopliteal Arteries- a Randomized Controlled Trial Terminated NCT00437905 Phase 4
29 Condition of Approval Study Terminated NCT00517751 Phase 4
30 Effects of X-STOP® Versus Laminectomy Study Withdrawn NCT00558129 Phase 4
31 Adenosine-induced Myocardial Blood Flow in Peripheral Artery Disease Patients Withdrawn NCT02121288 Phase 4
32 PROVIDENCE-1: Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients Unknown status NCT00251849 Phase 3
33 Autologous Bone Marrow-derived Mononuclear Cells for Therapeutic Arteriogenesis in Patients With Limb Ischemia Unknown status NCT00539266 Phase 2, Phase 3
34 Caffeine and Intermittent Claudication Completed NCT00388128 Phase 3
35 Effect of Niacin ER/Lovastatin on Peak Walking Time & Claudication Onset Time in Patients With Intermittent Claudication Completed NCT00062556 Phase 3
36 The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients With Intermittent Claudication - TROPIC Completed NCT00071266 Phase 3
37 Prostaglandin E1 in Outpatients With Intermittent Claudication Completed NCT01263925 Phase 3
38 Safety and Efficacy of Propionyl-L-Carnitine in the Treatment of Peripheral Arterial Disease (Intermittent Claudication) Completed NCT00399919 Phase 3
39 ARREST PAD (Peripheral Arterial Disease) Completed NCT00153166 Phase 2, Phase 3
40 Strength Training in Walking Tolerance in Intermittent Claudication Patients Completed NCT00879697 Phase 3
41 Evaluating Two Exercise Training Programs to Reduce Leg Pain in People With Peripheral Arterial Disease (The EXERT Study) Completed NCT00895635 Phase 3
42 Dacron vs Dardik for Fem-Pop Bypass Completed NCT00523263 Phase 3
43 Does the Reduction of Total Body Iron Storage (TBIS) Alter Mortality in a Population of Patients With Advanced PVD? Completed NCT00032357 Phase 3
44 Safety and Efficacy of Express LD to Treat Stenosed or Occlusive Atherosclerotic Disease in Iliac Arteries Completed NCT00352222 Phase 3
45 A Clinical Study on Efficacy & Safety Profile of Propionyl-L-carnitine Tablets for Peripheral Arterial Diseases Completed NCT00809497 Phase 3
46 Intensive Rehabilitation in Peripheral Arterial Disease With Claudication: Effects of a Treadmill Training With Active Recovery Completed NCT01734603 Phase 3
47 Paclitaxel Eluting Stent in Long SFA Obstruction: A Prospective, Randomized Comparison With Bypass Surgery Recruiting NCT01450722 Phase 3
48 Efficacy of Sildenafil on the Morbi-mortality of Peripheral Arterial Diseased Patients With Intermittent Claudication Not yet recruiting NCT02930811 Phase 3
49 Effect of Transcutaneous Electrical Nerve Stimulation in Peripheral Artery Disease TENS-PAD Study / TENS-AOMI Not yet recruiting NCT02678403 Phase 3
50 The Effects of Fish Oil Supplements During Supervised Exercise Therapy in Patients With Intermittent Claudication Terminated NCT02152930 Phase 3

Search NIH Clinical Center for Intermittent Claudication

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Intermittent Claudication cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: intermittent claudication

Genetic Tests for Intermittent Claudication

Anatomical Context for Intermittent Claudication

MalaCards organs/tissues related to Intermittent Claudication:

39
Endothelial, Smooth Muscle, Testes, Bone, Skin, Eye, Skeletal Muscle
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Intermittent Claudication:
id Tissue Anatomical CompartmentCell Relevance
1 Placenta Chorionic Villus Chorionic Mesenchymal Stromal Cells Potential therapeutic candidate

Publications for Intermittent Claudication

Articles related to Intermittent Claudication:

(show top 50) (show all 623)
id Title Authors Year
1
Baseline assessment and comparison of arterial anatomy, hyperemic flow, and skeletal muscle perfusion in peripheral artery disease: The Cardiovascular Cell Therapy Research Network "Patients with Intermittent Claudication Injected with ALDH Bright Cells" (CCTRN PACE) study. ( 27979038 )
2017
2
Long-term outcomes of a randomized clinical trial of supervised exercise, percutaneous transluminal angioplasty or combined treatment for patients with intermittent claudication due to femoropopliteal disease. ( 27763685 )
2017
3
Changes in Function After a 6-Month Walking Intervention in Patients With Intermittent Claudication Who Are Obese or Nonobese. ( 27341324 )
2016
4
Patient education interventions to improve physical activity in patients with intermittent claudication: a protocol for a systematic mixed-studies review. ( 27207628 )
2016
5
Reproducibility of Anaerobic and Pain Thresholds in Male Patients With Intermittent Claudication. ( 26959497 )
2016
6
A systematic review of the uptake and adherence rates to supervised exercise programmes in patients with intermittent claudication. ( 27126713 )
2016
7
Patterns and determinants of use of pharmacological therapies for intermittent claudication in outpatients with peripheral artery disease. Results of the IDOMENEO study. ( 27598470 )
2016
8
Revascularisation plus supervised exercise is superior to supervised exercise alone for the treatment of intermittent claudication. ( 26864898 )
2016
9
Altered joint kinematics and increased electromyographic muscle activity during walkingA in patients with intermittent claudication. ( 26781076 )
2016
10
The effect of supervised exercise therapy for intermittent claudication on lower limb lean mass. ( 27633168 )
2016
11
Run-Off Computed Tomography Angiography (CTA) for Discriminating the Underlying Causes of Intermittent Claudication. ( 27054846 )
2016
12
Comparison of use of Short Form-36 domain scores and patient responses for derivation of preference-based SF6D index to calculate quality adjusted life years (QALYs) in patients with intermittent claudication. ( 27177712 )
2016
13
Two-year results from a randomized clinical trial of revascularization in patients with intermittent claudication. ( 27220310 )
2016
14
Effect of diabetes mellitus on walking distance parameters after supervised exercise therapy for intermittent claudication: A systematic review. ( 27903955 )
2016
15
Self-administered versus interview-based questionnaires among patients with intermittent claudication: Do they give different results? A cross-sectional study. ( 26786606 )
2016
16
How Well Do Randomized Controlled Trials Reflect Standard Care: A Comparison between Scientific Research Data and Standard Care Data in Patients with Intermittent Claudication undergoing Supervised Exercise Therapy. ( 27336741 )
2016
17
Minimal correlation between physical exercise capacity and daily activity in patients with intermittent claudication. ( 26806522 )
2016
18
Raison d'etre of Tibial Artery Bypass for Intermittent Claudication in the Era of Endovascular Therapy. ( 27194373 )
2016
19
Cauda equina conduction time determined by F-waves in normal subjects and patients with neurogenic intermittent claudication caused by lumbar spinal stenosis. ( 27753733 )
2016
20
A Systematic Review of Extracorporeal Shockwave Therapy as a Novel Treatment for Intermittent Claudication. ( 27311948 )
2016
21
Understanding Patient Acceptance of Risk with Treatment Options for Intermittent Claudication. ( 27908805 )
2016
22
The impact of clinical, psychological, behavioral, social, and environmental factors on self-perceived symptom severity in a male cohort with intermittent claudication. ( 26821592 )
2016
23
Graduated Compression Stockings Does Not Decrease Walking Capacity and Muscle Oxygen Saturation during 6-Minute Walk Test in Intermittent Claudication Patients. ( 27932292 )
2016
24
Additional functional outcomes after endovascular treatment for intermittent claudication. ( 27872352 )
2016
25
Padma 28 for intermittent claudication. ( 27021597 )
2016
26
Minimally Important Difference of the Absolute and Functional Claudication Distance in Patients with Intermittent Claudication. ( 26715076 )
2016
27
Transcutaneous Electrical Nerve Stimulation Improves Walking Performance in Patients With Intermittent Claudication. ( 27299758 )
2016
28
Factors Associated with Sedentary Behavior in Patients with Intermittent Claudication. ( 27769867 )
2016
29
Compared to Intermittant Claudication Critical Limb Ischemia Is Associated with Elevated Levels of Cytokines. ( 27611073 )
2016
30
Outcomes of Open and Endovascular Lower Extremity Revascularization in Current Smokers With Intermittent Claudication and Critical Limb Ischemia. ( 27763293 )
2016
31
Analysis of isokinetic muscle function and postural control in individuals with intermittent claudication. ( 26786077 )
2016
32
Interspinous process devices for the treatment of neurogenic intermittent claudication: a systematic review of randomized controlled trials. ( 27178046 )
2016
33
Determining the Minimally Important Difference for the VascuQol Sumscore and Its Domains in Patients with Intermittent Claudication. ( 26837479 )
2016
34
Cost-effectiveness of supervised exercise therapy compared with endovascular revascularization for intermittent claudication. ( 27513296 )
2016
35
Review of research article: Comparison ofA two treadmill training programs on walking ability and endothelial function inA intermittent claudication by Mika P, Konik A, Januszek T, Nowobilski R, Nizankowski R, Szczeklik A (Int J CardiolA 2013; 168: 838-842). ( 27568319 )
2016
36
Capillary ultrastructure and mitochondrial volume density in skeletal muscle in relation to reduced exercise capacity of patients with intermittent claudication. ( 27009051 )
2016
37
TCT-788 Safety and Efficacy of Endovascular Therapy for Octogenarians with Peripheral Artery Disease presenting Intermittent Claudication due to Aortoiliac Lesions. ( 27970174 )
2016
38
Integrative therapy in patients with intermittent claudication. ( 25698386 )
2015
39
A systematic review of treatment of intermittent claudication in the lower extremities. ( 25721067 )
2015
40
Test-retest Reliability and Measurement Error Are Excellent for the Dutch Version of the VascuQol Questionnaire in Patients with Intermittent Claudication. ( 26264883 )
2015
41
Re: 'why do health systems not fund supervised exercise programmes for intermittent claudication?'. ( 25725509 )
2015
42
Functional independence measure in patients with intermittent claudication. ( 26516744 )
2015
43
Association between the ankle-brachial index, intermittent claudication, and physical activity level: what is the influence on the functional capacity of patients with or at high risk of cardiovascular disease? ( 25670912 )
2015
44
Lower functional capacity is associated with higher cardiovascular risk in Brazilian patients with intermittent claudication. ( 25700734 )
2015
45
Time-dependent effect of preinfarction angina pectoris and intermittent claudication on mortality following myocardial infarction: A Danish nationwide cohort study. ( 25846654 )
2015
46
"Standing still in the street": experiences, knowledge and beliefs of patients with intermittent claudication--a qualitative study. ( 25700732 )
2015
47
Absence of Preceding Intermittent Claudication and its Associated Clinical Freatures in Patients with Critical Limb Ischemia. ( 25739923 )
2015
48
A session of resistance exercise increases vasodilation in intermittent claudication patients. ( 25485893 )
2015
49
Gender differences following supervised exercise therapy in patients with intermittent claudication. ( 26304482 )
2015
50
Serum concentrations of l-arginine and l-homoarginine in male patients with intermittent claudication: A cross-sectional and prospective investigation in the CAVASIC Study. ( 25746168 )
2015

Variations for Intermittent Claudication

Expression for Intermittent Claudication

Search GEO for disease gene expression data for Intermittent Claudication.

Pathways for Intermittent Claudication

GO Terms for Intermittent Claudication

Cellular components related to Intermittent Claudication according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.97 ACE ALB APOH CRP F2 SERPINC1
2 extracellular region GO:0005576 9.65 ACE ALB APOH CRP F2 IL6
3 endoplasmic reticulum lumen GO:0005788 9.62 ALB F2 IL6 SERPINC1
4 external side of plasma membrane GO:0009897 9.56 ACE F2 IL6 SELP
5 platelet alpha granule lumen GO:0031093 9.46 ALB SERPINE1 VEGFA VWF
6 extracellular space GO:0005615 9.32 ACE ALB APOH CRP F2 IL6

Biological processes related to Intermittent Claudication according to GeneCards Suite gene sharing:

(show all 19)
id Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.78 ALB F2 IL6 SERPINC1
2 regulation of cell shape GO:0008360 9.75 F2 IL6 VEGFA
3 platelet activation GO:0030168 9.74 F2 IL6 VWF
4 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.71 HTR2A IL6 VEGFA
5 response to wounding GO:0009611 9.67 F2 IL6 VWF
6 defense response to Gram-negative bacterium GO:0050829 9.63 IL6 SELP SERPINE1
7 hemostasis GO:0007599 9.61 F2 SERPINC1 VWF
8 fibrinolysis GO:0042730 9.58 F2 SERPINE1
9 positive regulation of leukocyte migration GO:0002687 9.56 SELP VEGFA
10 negative regulation of blood coagulation GO:0030195 9.55 APOH SERPINE1
11 acute-phase response GO:0006953 9.54 CRP F2 IL6
12 neutrophil mediated immunity GO:0002446 9.52 ACE IL6
13 negative regulation of lipid storage GO:0010888 9.51 CRP IL6
14 regulation of blood coagulation GO:0030193 9.5 APOH F2 SERPINC1
15 blood coagulation, intrinsic pathway GO:0007597 9.43 APOH F2 VWF
16 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.4 ACE VEGFA
17 positive regulation of blood coagulation GO:0030194 9.33 APOH F2 SERPINE1
18 negative regulation of fibrinolysis GO:0051918 9.13 APOH F2 SERPINE1
19 platelet degranulation GO:0002576 9.1 ALB APOH SELP SERPINE1 VEGFA VWF

Molecular functions related to Intermittent Claudication according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 9.43 SERPINC1 SERPINE1 VWF
2 drug binding GO:0008144 9.33 ACE ALB HTR2A
3 lipopolysaccharide binding GO:0001530 9.32 F2 SELP
4 glycoprotein binding GO:0001948 9.13 APOH SELP VWF
5 heparin binding GO:0008201 9.02 APOH F2 SELP SERPINC1 VEGFA

Sources for Intermittent Claudication

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....